Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: REVLIMID

« Back to Dashboard

Summary for Tradename: REVLIMID

Patents:24
Applicants:1
NDAs:1
Suppliers: see list1

Pharmacology for Tradename: REVLIMID

Clinical Trials for: REVLIMID

Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
Status: Recruiting Condition: Multiple Myeloma

A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
Status: Completed Condition: Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)

Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma
Status: Recruiting Condition: Multiple Myeloma

Dasatinib in Combination With Revlimid (and Dexamethasone)
Status: Completed Condition: Multiple Myeloma

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Status: Active, not recruiting Condition: Follicular Lymphoma; Marginal Zone B-Cell Lymphoma; MALT Lymphoma; Lymphoma of Mucosa-Associated Lymphoid Tissue; Lymphoma, Small Lymphocytic; Waldenstrom Macroglobulinemia; Mantle-Cell Lymphoma

Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma
Status: Recruiting Condition: Myeloma

Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
Status: Terminated Condition: Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma

Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Status: Recruiting Condition: Relapsed Multiple Myeloma

Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Status: Active, not recruiting Condition: Refractory Multiple Myeloma; Relapsed Multiple Myeloma; Multiple Myeloma

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)
Status: Completed Condition: HIV-1 Infection

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Celgene
REVLIMID
lenalidomide
CAPSULE;ORAL021880Dec 21, 2011RXNo8,741,929<disabled><disabled>
Celgene
REVLIMID
lenalidomide
CAPSULE;ORAL021880Jun 5, 2013RXNo7,468,363<disabled><disabled>
Celgene
REVLIMID
lenalidomide
CAPSULE;ORAL021880Jun 29, 2006RXYes6,281,230<disabled><disabled>
Celgene
REVLIMID
lenalidomide
CAPSULE;ORAL021880Jun 29, 2006RXYes<disabled><disabled>
Celgene
REVLIMID
lenalidomide
CAPSULE;ORAL021880Jun 5, 2013RXNo6,561,977<disabled><disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: REVLIMID

Drugname Dosage Strength RLD Submissiondate
lenalidomideCapsules5 mg, 10 mg and 15 mgRevlimid8/30/2010
lenalidomideCapsules25 mgRevlimid7/12/2010
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc